Other languages XOMA Corporation Nasdaq

Equities

XOMAO

US98419J4040

Market Closed - Nasdaq Other stock markets 02:00:01 18/05/2024 am IST			5-day change	1st Jan Change
25.1 ^USD	0.00%		0.00%	-0.08%

09/05	Earnings Flash (XOMA) XOMA CORPORATION Reports Q1 Revenue $1.5M	MT
09/05	XOMA Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

XOMA Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
XOMA Corporation completed the acquisition of three First-in-Category Assets of Daré Bioscience, Inc. for $22 million.	30/04
XOMA Corporation completed the acquisition of Kinnate Biopharma Inc..	03/04
XOMA Corporation Reports Earnings Results for the Full Year Ended December 31, 2023	08/03
Sector Update: Health Care Stocks Advance Friday Afternoon	17/02
XOMA Agrees to Acquire Kinnate Biopharma	16/02
XOMA Acquires Interest in Pain Management Medication Dsuvia for $8 Million	18/01
XOMA Corporation acquired DSUVIA® of Talphera, Inc. for $8 million.	18/01
XOMA Names Owen Hughes CEO, Jack Wyszomierski Chairman; to Make $1 Million Milestone Payment	12/01
Xoma Names Owen Hughes as Chief Executive Officer	08/01
Xoma Appoints Jack L. Wyszomierski as Chairman of the Board of Directors	08/01
XOMA Authorizes $50 Million Share Buyback Program	02/01
XOMA Authorizes $50 Million Share Buyback Program	02/01
XOMA Corporation announces an Equity Buyback for $50 million worth of its shares.	02/01
XOMA Corporation authorizes a Buyback Plan.	02/01
Sector Update: Health Care Stocks Gain in Afternoon Trading	20/12
Xoma Gets Up To $140 Million Royalty-Backed Loan From Blue Owl Capital; Xoma Shares Rise	19/12
Xoma-Non-Dilutive, Non-Recourse, Royalty-Backed Loan For Up To $140 Million Of Capital	19/12
XOMA Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	07/11
XOMA Earns $5 Million Milestone Upon US FDA Acceptance of Day One Biopharmaceuticals' NDA for Glioma Therapy	31/23/31

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages XOMA Corporation Nasdaq

Equities

XOMAO

US98419J4040

Other languages

Filters